联影医疗(688271.SH)发布2025年度业绩快报，公司2025年度实现营业总收入138.21亿元，同比增长 34.18%;实现归属于母公司所有者的净利润18.88亿元，同比增长49.60%。 报告期内，公司围绕长期竞争力建设，系统推进创新产品导入、全球市场布局深化、供应链体系优化及 核心技术能力积累。中国市场在大规模医疗设备更新政策于2025年进入常态化、专业化实施阶段的背景 下，高端医学影像、放疗及基层诊疗能力建设相关设备需求持续释放，行业整体规模较上年同期明显回 升。公司在国内市场占有率持续提升并保持行业领先地位，中国市场收入规模实现显著增长，经营质量 与盈利能力同步增强。 ...

中新网武汉1月22日电 湖北省"51020"先进制造业集群产业生态之医工交叉产业对接活动22日在武汉举 行，湖北省医工交叉融合创新产业联盟正式揭牌成立，31项医工交叉融合创新项目及产业化项目达成合 作，意向投资总额约12亿元，涉及医工交叉产业全链条合作，涵盖产学研医融全生态协同。 湖北省医工交叉融合创新产业联盟，是在湖北省经信厅、湖北省卫健委、湖北省药监局等部门指导下组 建的省级医工融合创新转化平台。该联盟汇聚医疗机构、高校院所、投融资机构、医药龙头及专业服务 机构等多家核心单位，构建起"临床需求—技术研发—中试熟化—资本赋能—产业落地"的全链条创新生 态体系。 现场，湖北省2025年医工交叉揭榜挂帅十大创新项目正式发布。湖北省经信厅将对揭榜项目给予最高 500万元资金扶持，推动创新链、产业链、资金链深度融合，加速以生物医药为核心的大健康产业高质 量发展。(完) （文章来源：中国新闻网） 湖北省医工交叉融合创新产业联盟理事长马丁表示，联盟将动员平台机构和医药企业力量，聚焦科创成 果转化早介入、早对接、早融合，在概念验证、中试熟化、临床研究、法规认证、产业化等各环节进行 孵化，培育更多医疗创新型科技企业，不断壮 ...

Core Viewpoint - The 15th China Medical Device Supervision International Conference opened in Suzhou, focusing on innovation and regulation in the medical device industry, with significant support from government officials and industry leaders [1][2]. Group 1: Government Support and Initiatives - The National Medical Products Administration (NMPA) has concentrated on key areas such as medical robots, high-end medical imaging, AI medical devices, and new biomaterials, supporting the innovation of high-end medical devices [1]. - In 2023, the NMPA has approved 52 innovative products, bringing the total to 367 approved innovative products to date [1]. - The government aims to implement reforms to promote high-quality development in the pharmaceutical and medical device industries, encouraging global medical device products to debut in China [1]. Group 2: Regional Development and Investment Opportunities - Jiangsu province plans to leverage the conference to explore new paths and models for medical device innovation and regulation, aiming to elevate the industry to a higher level [1]. - The province welcomes global pharmaceutical companies to invest and deepen their presence in Jiangsu, aiming to create a hub for innovation, quality, and openness in the global medical device industry [1]. - Jiangsu will continue to optimize the business environment, focusing on the entire lifecycle of product development, transformation, and project implementation to enhance its reputation as a premier business destination [1].